Innate Pharma (IPH) investor relations material

Portfolio strategy

• Focused oncology portfolio combines partnered late-stage assets with a wholly owned Nectin-4 ADC and a preclinical ADC pipeline built on proprietary linker technology.

• Lacutamab’s estimated peak-year sales potential is >$500M in the US, EU4 and UK, based on management estimates.

Lacutamab

• Phase 2 TELLOMAK SS cohort (N=63; post-mogamulizumab, ≥2 prior systemic lines): ORR 42.9%, median DoR 25.6 months and median PFS 8.3 months.

• In MF (N=107; ≥2 prior systemic lines), ORR was 19.6%, median DoR 13.8 months and median PFS 10.2 months; responses occurred across KIR3DL2 expression levels.

• TELLOMAK-3 Phase 3 is initiated; first patient is planned in Q1 2027, with an accelerated approval filing in SS planned for H2 2027 based on Phase 2 data.

• Sobi partnership terms include $75M upfront, up to $40M in near-term SS milestones, up to an additional $465M in option and regulatory/commercial milestones, and tiered double-digit royalties.

IPH4502

• Wholly owned Nectin-4 exatecan ADC uses a DAR8 design, proprietary humanized antibody and cleavable linker; preclinical work supports activity in EV-resistant and low or heterogeneous Nectin-4 models.

• Phase 1 dose-escalation enrollment was completed; preliminary objective responses were observed in post-EV urothelial cancer, NSCLC and HNSCC, with a favorable safety profile and limited hematological toxicity to date.

• Initial Phase 1 dose-escalation data were planned for ENA 2026; the study includes dose escalation of up to 76 patients and dose optimization of up to 60 patients.